Oncoinvent ASA · OSL:ONCIN
Oncoinvent ASA — Investor Presentation (February 2024)
25 slides from Oncoinvent ASA's investor presentation, February 2024
Slide 1: Corporate Presentation
Corporate Presentation Developing a New Standard Therapy for Peritoneal Carcinomatosis (PC) with a local, receptor independent, radiopharmaceutical technology
Slide 2: Oncoinvent: Investment Opportunity
Oncoinvent: Investment Opportunity Radiopharma hot-spot 1 Rapidly growing development area in oncology, substantial interest from investors and Big Pharma. 1 Experienced Leadership 2 Founders and management of Oncoinvent have a proven track record of developing a 2 radiopharmaceutical asset and brin
Slide 3: Radiopharmaceuticals Market Opportunity in Oncology - Investments
Radiopharmaceuticals is a lucrative and untapped Market Opportunity in Oncology - Investments • Radiopharmaceuticals have seen a recent surge of financings and acquisitions, creating a new attractive hot spot in oncology • The space is projected to experience continued growth and is positioned to su
Slide 4: Radiopharmaceuticals Market Opportunity in Oncology - Acquisitions
Radiopharmaceuticals is a lucrative and untapped Market Opportunity in Oncology - Acquisitions • Radiopharmaceuticals have seen a recent surge of financings and acquisitions, creating a new attractive hot spot in oncology • The space is projected to experience continued growth and is positioned to s
Slide 5: Experienced Developers in Innovative Radiopharmaceuticals
Experienced Developers in Innovative Radiopharmaceuticals Radiochemistry and Preclinical Expertise Encouraging Clinical Data and Upcoming Milestones Expert founders and management with decades of experience in developing alpha-emitting therapies for Clinical studies of Radspherin demonstrate excelle
Slide 6: Leadership Team Experienced in Building Companies and Bringing Radiopharmaceutical Therapy to Market
Leadership Team Experienced in Building Companies and Bringing Radiopharmaceutical Therapy to Market Anders Mansson Gro Hjellum Anne-Kirsti Aksnes Kari Myren Tore Kvam Chief Executive Officer Chief Operations Officer Chief Clinical Officer Chief Medical Officer Chief Financial Officer 6
Slide 7: Body Cavity Targeting - Peritoneal Carcinomatosis
Body Cavity Targeting - Peritoneal Carcinomatosis - A multiple cancer type disease area with a significant unmet medical need • Tumors of the peritoneum are most frequently Secondary extraperitoneal origin Secondary intraperitoneal origin caused by metastases from other primary Lung cancer Cholangio
Slide 8: Peritoneal Carcinomatosis – Room for Further Expansion
Peritoneal Carcinomatosis – Room for Further Expansion - Addressable market, beyond ph3 target, with significant unmet medical need Long-term survival rates of patients with PC Five-year survival rates in ovarian cancer2 by disease stage of colorectal origin1 90% 78% 70% 39% 36% 24% 17% 1 year 3 yea
Slide 9: Clinical Administration of Radspherin®
Clinical Administration of Radspherin® - Delivering highly effective receptor-independent alpha-therapy directly to target area • A catheter is left after Cytoreductive Surgery (CRS) • Through that catheter a single dose of Radspherin® microparticles, dispersed in a solution, are injected directly i
Slide 10: Radspherin® for the Treatment of Peritoneal Metastasis
Radspherin® for the Treatment of Peritoneal Metastasis - Delivering highly effective receptor independent alpha-therapy directly to target area • Non-systemic, single-dose, intraperitoneal Radspherin® aims to eliminate residual micro-metastases after cytoreductive surgery and thus prolong disease-fr
Slide 11: Radspherin® - Clinical Development
Radspherin® - Clinical Development - Clinical dose established, enrollment to phase 2a in completion • Two Phase 1/2a studies - assessing dose, safety and tolerability, dosimetry and signal of efficacy of intraperitoneal Radspherin • Oslo/Norway(PI: Yun Wang) RAD-18-001: Ovarian/fallopian tube cance
Slide 12: Radspherin® Robust Safety Profile
Radspherin® Robust Safety Profile - Well tolerated and minimal organ toxicity • No dose limiting toxicities observed at any dose level Well tolerated and considered safe to use • Well tolerated with only grade 1-2 events reported as possibly related to Radspherin® Clinically relevant dose determined
Slide 13: Clinical Phase 1/2a
Clinical Phase 1/2a - No peritoneal recurrences in recommended dose group after 18 months in 1st cohort! • Expected median time to progression after current standard treatment (CRS-HIPEC) is around 12 months • After 18 months, ca. 70% of patients have recurrencies overall and >50% have recurrences i
Slide 14: Radspherin® - Local & Overall DFS Plotting in CRC
Radspherin® - Local & Overall DFS Plotting in CRC - 18 months interim efficacy analysis phase 1/2a (n=22) • Disease-free survival at 18 months after the addition of 7 MBq Radspherin® to CRS-HIPEC was 67 % (n=12) Kaplan-Meyer curve of local disease-free survival Kaplan-Meyer curve of overall disease-
Slide 15: Radiopharmaceuticals Manufacturing Excellence
Radiopharmaceuticals Manufacturing Excellence • Reliable supply of the starting-material, radioisotope, Thorium-228. In- house production of Radium-224. • Internal expertise in development, manufacturing and quality control of radiopharmaceuticals. • In-house, state-of-the-art GMP production of Rads
Slide 16: Scenario 0
Scenario 0 2024 2025 2026 2027 2028 2029 2030 15 M USD 15 M USD 15 M USD 15 + 5 + 5 M USD (2 x TT)? = 70 M USD Funding required: Full Full Milestones: 12m CRC OC 9m Full Conditional Full Ph2a Ph2a Ph2a Ph2b Ph2b Approval? Ph3 Ph1/Ext OC 11 Follow-up Ovarian IND Ph2b OC 60/30 Recr. Ph2b OC 60/30 Foll
Slide 17: Scenario 1
Scenario 1 2024 2025 2026 2027 2028 2029 2030 10 M USD 10 M USD 15 M USD 15 + 5 + 5 M USD (2 x TT)? = 60 M USD Funding required: Full Full Milestones: 12m CRC OC 9m Full Conditional Full Ph2a Ph2a Ph2a Ph2b Ph2b Approval? Ph3 Ph1/Ext OC 11 Follow-up Ovarian IND Ph2b OC 60/30 Recr. Ph2b OC 60/30 Foll
Slide 18: Identified Partner Candidates
Identified Partner Candidates CRC / Ovarian Cancer CRC / Ovarian Cancer & Radio pharmaceuticals Radiopharmaceuticals ! 18
Slide 19: Oncoinvent: Investment Opportunity
Oncoinvent: Investment Opportunity Radiopharma hot-spot 1 Rapidly growing development area in oncology, substantial interest from investors and Big Pharma. 1 Experienced Leadership 2 Founders and management of Oncoinvent have a proven track record of developing a 2 radiopharmaceutical asset and brin
Slide 20: Thank You
Thank You www.oncoinvent.com [email protected]
Slide 21: Appendix
Onc~e invent Appendix
Slide 22: Radspherin® Target Population – Ovarian Cancer
Radspherin® Target Population – Ovarian Cancer Number of Ovarian Cancer Patients in Target Group (US & Europe) %-age US Europe Total Reference All patients newly diagnosed with epithelial ovarian cancer 24,480 69,470 93,950 Globocan, accessed 5 Feb 2024 Of which, epithelial ovarian cancer 90% 22,032
Slide 23: Radspherin® Target Population – Colorectal Cancer
Radspherin® Target Population – Colorectal Cancer Number of Colorectal Cancer Patients in Target Group (US & Europe) %-age US Europe Total Reference All patients newly diagnosed with colorectal cancer (all stages) 184,000 540,000 724,000 Globocan, accessed 13 Feb 2024 Of which, are patients with Sta
Slide 24: Radspherin® Radiopharmaceutical Pricing Benchmarks
Radspherin® Radiopharmaceutical Pricing Benchmarks Product PFS Benefit OS Benefit Price • Radspherin® has a targeted PFS Xofigo N/A 3.6 m USD 69.000 improvement of 12 months Lutathera 8.5 m N/A USD 190.000 and a minimum acceptable profile of 6 months. Pluvicto N/A 4.0 m USD 255.000 PFS = Progression
Slide 25: Key Tenets of an Oncoinvent Business Case
Key Tenets of an Oncoinvent Business Case • Targeted Patient Population: 22.000 – 50.000 eligible patients per year (US & Europe) • Peak Penetration Estimate (assuming Standard of Care): 70% and rapid uptake • Average Pricing Estimate given PFS Target: 50.000 USD per treatment (lower range estimate)